N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early
phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and
Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur
during the pre-illness phase and around the transition to psychosis. Therefore, studying new
treatments that could target changes occurring during this period is of critical importance.
Aims:
Does add-on NAC treatment in early psychosis influence:
- positive and negative symptoms
- extrapyramidal side-effects of other medication
- plasma concentration of glutathione
- Mismatch Negativity, a physiological marker
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborator:
Center de Neurosciences Psychiatrique, Lausanne, Switzerland